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SUMMARY
During mammalian development, liver differentiation is driven by signals that converge on multiple
transcription factor networks. The hepatocyte nuclear factor signaling network is known to be essen-
tial for hepatocyte specification andmaintenance. In this study, we have generated deletion and point
mutants of hepatocyte nuclear factor-4alpha (HNF4a) to precisely evaluate the function of protein
domains during hepatocyte specification from human pluripotent stem cells. We demonstrate that
nuclear HNF4a is essential for hepatic progenitor specification, and the introduction of point muta-
tions in HNF4a0s Small Ubiquitin-like Modifier (SUMO) consensus motif leads to disrupted hepatocyte
differentiation. Taking a multiomics approach, we identified key deficiencies in cell biology, which
included dysfunctional metabolism, substrate adhesion, tricarboxylic acid cycle flux, microRNA trans-
port, and mRNA processing. In summary, the combination of genome editing and multiomics analyses
has provided valuable insight into the diverse functions of HNF4a during pluripotent stem cell entry
into the hepatic lineage and during hepatocellular differentiation.
INTRODUCTION
Directed differentiation of human pluripotent stem cells offers robust systems to study gene function dur-
ing human development. Defined and efficient human hepatic differentiation systems have been
developed and automated, allowing detailed mechanistic studies to be performed (Hay et al., 2007,
2008; Lucendo-Villarin et al., 2017; Meseguer-Ripolles et al., 2018; Rashidi et al., 2018; Si-Tayeb et al.,
2010; Sullivan et al., 2010; Szkolnicka et al., 2014). These models have been sophisticated further using
modern genome editing systems. Recently, pluripotent stem cells with an albumin reporter system have
facilitated the discovery of key players involved in hepatocyte maturation (Li et al., 2018). In our study,
the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) endonu-
clease nickase was employed for hepatocyte nuclear factor-4alpha (HNF4a) genome editing in human
pluripotent stem cells.
HNF4a is a highly conserved transcription factor of the nuclear receptor superfamily (Sladek et al., 1990). It is a
modular protein containing five functional regions. Regions A and B contain the N-terminal transactivation
domain (AD-1), region C is a highly conserved zinc finger DNA-binding domain (DBD), region D is a flexible
hinge, region E is a multifunctional ligand-binding domain containing the second transactivation domain
(AD-2), and the repression region is located in region F (Lau et al., 2018). Both transactivation domains are
important to HNF4a-driven gene transcription (Dhe-Paganon et al., 2002). To understand which regions of
the HNF4a protein are required for directing cell specification and maturation, we used CRISPR-Cas9-based
genome editing technology to modify the DBD in the amino terminus, and AD-2 in the carboxy terminus.
Previous genome-wide location analysis revealed that HNF4a was bound to 12% of genes in human
hepatocytes, which was greater than other hepatocyte nuclear factors (Odom et al., 2004). Notably, 42%
of the actively transcribed genes occupied by RNA polymerase II were bound by HNF4a, demonstrating
its central role in hepatocyte biology (Odom et al., 2004). More recent researches showed that HNF4a
was essential to the formation of hepatic progenitors during human pluripotent stem cell differentiation
(DeLaForest et al., 2011, 2018). In these studies, HNF4a was required for the recruitment of RNA polymer-
ase II to genes that were specifically expressed at the hepatic progenitor stage (DeLaForest et al., 2018).
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Given its potent activity, HNF4a is regulated at numerous levels, which include nuclear receptor interac-
tion, microRNA (miRNA) regulation, and post-translational modification (Lau et al., 2018; Ramamoorthy
et al., 2012; Yokoyama et al., 2011). A number of post-translational modifications have been shown to regu-
late HNF4a protein stability, function, and subcellular localization (Jiang et al., 1997; Ktistaki et al., 1995;
Viollet et al., 1997; Yokoyama et al., 2011; Zhou et al., 2012). In addition, recent studies highlighted that
HNF4a protein stability is regulated post-translationally through interaction with heat shock protein 90 b
interaction (Jing et al., 2017). In these studies, we were particularly interested in HNF4a0s post-translational
modification by the Small Ubiquitin-like Modifier (SUMO) at a consensus motif in the AD-2 domain of the
carboxy terminus (Zhou et al., 2012).
This study examined HNF4a protein domain function during hepatoblast and hepatocyte specification
from pluripotent stem cells. Isogenic pluripotent stem cell lines, which possessed a truncation or point mu-
tations in HNF4a, were created and compared with a wild-type (WT) line. Pluripotent stem cells that
possessed the DNA-binding domain deletion mutant of HNF4a displayed defects in endoderm and
hepatic progenitor specification, whereas HNF4a point mutants failed to form functional hepatocytes,
with defects in cell metabolism, adhesion, tricarboxylic acid (TCA) cycle flux, miRNA transport, and
mRNA processing detected.
RESULTS
Generation and Characterization of HNF4a-Edited Pluripotent Stem Cell Lines
To reduce potential off-target effects, we used paired CRISPR-Cas9 nickases to edit HNF4a (Ran et al.,
2013). Two pairs of Cas9 nickases were utilized to delete the consensus exon 2 in HNF4a (Figure 1A, top
panel). The PCR product from amplification of the targeted region in a homozygous deletion mutant
cell line was smaller than the WT control (Figure 1A, middle panel). There was a 540- and 541-bp deletion
in each allele, respectively, which was confirmed by sequencing (Figure 1A, bottom panel). In parallel, two
point mutations (K365R and D367A) were introduced into the SUMOylation consensus motif in the
C terminus of HNF4a using Cas9 nickase and a piggyBac-based targeting vector (Zhou et al., 2012;
Yusa, 2013). PCR genotyping followed by sequencing identified the insertion of the selection cassette in
the targeted clones. The piggyBac repeats were inserted between 50- and 30-homology arms (Figure 1B,
middle panel). Post removal of the selection cassette, sequencing results confirmed the seamless editing
of this locus. In the point mutated clones, two point mutations were introduced into the HNF4a gene
(AAG to AGG, K365R; GAC to GCC, D367A). Four synonymous mutations were also introduced to allow
the integration of piggyBac (TTAA site) and to disrupt the protospacer-adjacent motif (PAM) sequence
for Cas9 nickases (Figure 1B, bottom panel).
Following genome editing, one WT, one homozygous deletion mutant (DBD Mut), and one point mutated
clone (SUMO Mut) were expanded, differentiated, and characterized in detail. Similar to the WT clone,
the DBD Mut and SUMO Mut clones possessed typical pluripotent stem cell morphology, more than
90% cells expressed NANOG and OCT4, as well as cell surface markers SSEA4 and TRA-1-60 (Figures
1C and 1D). See Table S7 for further details.
Hepatocyte Differentiation Was Perturbed in HNF4a-Edited Pluripotent Stem Cells
To study the effect of editing HNF4a in liver cells, we differentiated WT, DBD Mut, and SUMO Mut clones
towards hepatic lineage using a stage-wise differentiation protocol (Meseguer-Ripolles et al., 2018; Wang
et al., 2017). WT human embryonic stem cells transited through definitive endoderm stage (differentiation
day 3) (Figures S1A and S1B) and then gave rise to polygonal hepatic progenitors (differentiation day 9)
(Figure 2A). In contrast, the DBD Mut cells displayed cytoplasmic HNF4a, prolonged endoderm differen-
tiation, and failed to commit to hepatoblast lineage, demonstrated by the lack of alpha fetoprotein (AFP)
and CCAAT enhancer-binding protein alpha (CEBPA) expression (Figures 2A and S1). In contrast, the
SUMO Mut cells were comparable to the WT hepatoblast in terms of morphology, demonstrating nuclear
HNF4a, albeit with reduced levels of HNF1a, AFP, and CEBPA expression (Figures 2A, 2C, and S1C).
Western bloting demonstrated that the DBD Mut hepatic progenitor cell expressed a truncated form of
HNF4a, which was about 10 kDa smaller than the WT or SUMO Mut HNF4a (Figure 2B). Sequencing of
HNF4a cDNA in the DBD Mut cells confirmed that exons 2 and 3 were skipped in these cells, resulting
in the truncated form of HNF4a (Figure S2). A decrease in HNF4a expression was observed in all cell lines
between days 9 and 16, which was consistent with previous studies inWT cells (Zhou et al., 2012) (Figure 2B).
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In addition, real-time PCR confirmed higher levels of HNF4amRNA in the DBDMut progenitor cells than in
the WT or SUMO Mut cells (Figure 2C). Despite this, HNF4a in the DBD Mut cells failed to transactivate
HNF1a and AFP gene expression and yielded lower levels of transthyretin (TTR) (Figures 2A and 2C).
In addition, neither the DBD Mut nor the SUMO Mut cells could produce hepatocyte-like cells. Their mor-
phologies were different from each other and the WT control cells (Figure 2D). Functionally, the DBD Mut
cells had no detectable albumin or AFP secretion, or basal cytochrome P450 (CYP) 3A activity (Figure 2E),
demonstrating failed hepatoblast and hepatocyte differentiation. The SUMO Mut cells secreted AFP at
lower levels than the WT cells; however, they did not exhibit albumin secretion or basal CYP3A activity
when hepatocyte specification was induced, demonstrating failed hepatocyte specification (Figure 2E).
Figure 1. The Generation and Characterization of HNF4a Genome-Edited Cell Lines
(A) Two guide RNA pairs targeting introns 1 and 2 were used to delete exon 2 in HNF4a (top panel). A homozygous deletion clone was identified by
amplifying the targeted region (middle panel). Sequencing confirmed the deletion mutant (DBDMut) clone had a 540/541-bp deletion in each allele (bottom
panel). See Tables S5 and S6 for further details.
(B) A piggyBac-based targeting vector was used in combination with Cas9 nickases to introduce desired point mutations into HNF4a (top panel). The
targeted clones incorporated the selection cassette (middle panel). This selection cassette is contained within the piggyBac transposon and consists of a
positive-negative selection marker (puro-tk) expressed from a constitutively active promoter (PGK). Post excision of the transposon, the locus was modified
seamlessly (bottom panel). PAM, protospacer-adjacent motif; HA, homology arm; PB, piggyBac, 50-PB ITR and 30-PB ITR are 50 and 30 piggyBac inverted
terminal repeats flanked by the TTAA direct repeats. See Tables S5 and S6 for further details.
(C) Representative images of cellular morphology, immunofluorescences of NANOG and OCT4. One wild-type (WT) clone, one DBD Mut clone, and one
point-mutated (SUMO Mut) clone was selected for characterization. IgG was used as a negative control. The percentage was calculated using four random
fields of view. Scale bar, 100 mm for phase contrast and 50 mm for immunostaining images.
(D) Flow cytometry of SSEA4- and TRA-1-60-expressing cells in the WT, DBD Mut, and SUMO Mut clones. IgG was used as a negative control. N = 3
independent experiments.
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Disruption of Cellular Bioenergetics in HNF4a-Edited Cells during Cell Specification
To gain an understanding of the DBD Mut and SUMOMut cells at the hepatic progenitor stage (day 9), we
performed non-targeted profiling of metabolites using 1H nuclear magnetic resonance metabolomics
(Patti et al., 2012). The metabolic rate for each metabolite was quantified by normalizing the signal intensity
against the cell number at the detected time point. The unit for the metabolic rate was then recorded as
rate of integral area per cell. Negative and positive rate values indicate consumption and production
respectively. The DBD Mut and SUMO Mut cells had a significantly lower consumption rate for both
glucose and pyruvate than the WT control (Figure 3A). This was confirmed by reduced production rate
of lactate, formate, and acetate (Figure 3A) and suggests compromised glycolysis and pyruvate oxidation
or cycling in both cell lines. In addition, the DBDMut and SUMOMut cells possessed a lower consumption
rate of the essential amino acids threonine and tryptophan compared with the WT cells (Figure 3B). The
SUMO Mut cells also demonstrated slower consumption of valine, methionine, and phenylalanine than
both WT and DBD Mut cells (Figure 3B). Notably, the DBD Mut cells had the highest consumption rate
of isoleucine among the three cell types (Figure S3). The WT cells had significantly increased production
Figure 2. Hepatocyte Differentiation of HNF4a Genome-Edited Pluripotent Stem Cells
(A) Morphology and immunostaining of HNF4a and AFP in the differentiated cells at hepatic progenitor stage. Scale bar, 100 mm for phase contrast and
50 mm for immunostaining images.
(B) Western bloting for HNF4a in differentiated cells at days 9 (hepatic progenitor stage) and 16 (hepatocyte like cell). ACTIN was used as a loading control.
See Table S7 for further details.
(C) Real-time PCR quantification of HNF4a, HNF1a, and transthyretin (TTR) mRNA levels in hepatic progenitor stage (day 9) cells. Data were normalized to
the housekeeping gene ACTB and expressed relative to the WT cells. The results shown represent three biological replicates, and error bars represent SD.
*p < 0.05, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey post hoc test. See Table S8 for further details.
(D) Morphology of differentiated cells at hepatocyte-like cell stage (differentiation day 18). Scale bar, 100 mm.
(E) ELISA quantification of AFP and albumin secretion in differentiated cells at hepatocyte-like cell stage and quantification of cytochrome P450 3A (CYP3A)
activity. Data represented three biological replicates, and error bars represented SD. ***p < 0.001, ****p < 0.0001; one-way ANOVAwith Tukey post hoc test.
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of alanine and consumption of tyrosine and t-methylhistidine than the other cell lines (Figure S3). These
data demonstrated that amino acid metabolism and bioenergetics were disrupted in HNF4a DBD Mut
and SUMO Mut cells.
Transcriptomic Analysis of WT and HNF4a-Edited Hepatic Progenitor Stage Cells
The cellular phenotypes we observed highlighted that proper HNF4a function was vital to cell metabolism
and hepatocyte specification. To further understand the effect of HNF4a editing on hepatic progenitor cell
biology, transcriptomic profiles were generated for WT, DBD Mut, and SUMO Mut cells at differentiation
day 9. Principal-component analysis (PCA) of 1,000 genes with the highest variance demonstrated a clear
difference among DBDMut, SUMOMut, andWT (Figures 4A and S4). A set of 1,310 differentially expressed
genes (DEGs) was defined for further evaluation, which were either differential between the DBD Mut and
WT cells or between the SUMO Mut and WT cells (p value <0.05; 2-fold threshold, false discovery rate
adjusted; Table S1). Gene ontology (GO) enrichment analysis using the Enrichr web server (Chen et al.,
Figure 3. Metabolomic Studies in Hepatic Progenitor Stage Cells from WT and HNF4a Genome-Edited Pluripotent Stem Cells
(A) Metabolic rates of glucose, pyruvate, lactate, formate, and acetate in the WT, DBD Mut, and SUMO Mut cells.
(B) Metabolic rates of essential amino acids threonine, tryptophan, valine, methionine, and phenylalanine in the WT, DBD Mut, and SUMO Mut cells.
Data represent three biological replicates, and error bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey post
hoc test.
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2013; Kuleshov et al., 2016) showed that the 452 down-regulated genes unique to DBD Mut cells were en-
riched in biological processes such as ‘‘sterol import (GO:0035376)’’ and ‘‘cholesterol homeostasis (GO:
0042632)’’ (Figure 4B and Table S2). Representative genes included apolipoprotein A1 (APOA1),
APOA2, and low-density lipoprotein receptor (LDLR) (Figure 4D and Table S2). The expression of a number
of significantly down-regulated genes was confirmed by real-time PCR results, including APOA2, APOA4,
and 3-hydroxy-3-methylglutaryl-CoA synthase 1 and 2 (HMGCS1 and HMGCS2) (Figure 4E). We also de-
tected 215 unique up-regulated genes in the DBD Mut cells. Those were most enriched in pathways like
‘‘transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178)’’ and ‘‘skeletal
system development’’ (Figure 4B and Table S2). The representative genes included bone morphogenetic
protein 5 (BMP5) and SMAD9 (Figure 4D and Table S1). Interestingly, all up-regulated genes in the DBD
Mut cells compared with the WT control showed features for ectoderm differentiation (Table S2). When
combined, these specific DEGs in the Del Mut cells were most enriched in cholesterol homeostasis,
Figure 4. Transcriptomic Analysis of Hepatic Progenitor Stage Cells from WT and HNF4a Genome-Edited Pluripotent Stem Cells
(A) Principal-component analysis of the three types of cells (n = 3 replicates) based on 1,000 genes with the highest variance.
(B) Top five enriched biological processes of the significantly down- or up-regulated genes specific in the DBD Mut cells. Pathway enrichment was analyzed
using Enrichr web server.
(C) Top five enriched biological processes of the significantly down- or up-regulated genes unique to the SUMOMut cells. Pathway enrichment was analyzed
using Enrichr web server.
(D) Fold changes of representative genes in the DBD Mut and SUMO Mut cells compared with the WT control from the microarray analysis. The gene
expression levels have been log2 transformed.
(E) Real-time PCR results of representative genes APOA2, APOA4, HMGCS1, HMGCS2, laminin subunit beta 3 (LAMB3), and fibrinogen alpha chain (FGA).
Data were normalized to the housekeeping gene ACTB and expressed relative to the WT cells. The results shown represent three biological replicates, and
error bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey post hoc test. See Table S8 for further details.
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extracellular matrix (ECM) organization, alpha-amino acid catabolic process, and cytoskeleton organiza-
tion regulation (Table S2). Taken together, the HNF4a DBD domain is essential for the expression of genes
important for cell metabolism, ECM, and cytoskeleton organization during hepatoblast specification.
We also analyzed the specific DEGs in the SUMOMut cells to understand the effect of modifying the HNF4a
SUMOmotif. We detected 260 down-regulated genes specific to the SUMOMut cells. Those were enriched
for biological processes including ‘‘negative regulation of transcription (GO:0045892)’’ and ‘‘regulation of
transcription from RNA polymerase II promoter (GO:0006357)’’ (Figure 4C and Table S2). Genes such as
the forkhead box protein C1 and O3 (FOXC1 and FOXO3) were significantly down-regulated (Figure 4D
and Table S1).We also detected 141 up-regulated genes enriched for processes like ‘‘sulfur compound cata-
bolic process (GO:0044273)’’ and ‘‘JAK-STAT cascade (GO:0007259)’’ (Figure 4C and Table S2). Represen-
tative genes included ChaC glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) and signal
transducer and activator of transcription 4 (STAT4) (Figure 4D and Table S1). Combining the significantly
down- and up-regulated genes together, the most enriched biological process was negative regulation
of gene transcription (Table S2). Collectively, the introduced point mutations in the HNF4a SUMO
consensus motif most likely affected gene transcription necessary for successful hepatocyte specification.
We also studied transcriptomic differences between the different mutant forms of HNF4a; 584 genes were
down-regulated in the DBD Mut cells when compared with the SUMO Mut. They were mainly enriched in
cholesterol homeostasis and lipoprotein remodeling. There were also 242 genes up-regulated in the DBD
Mut cells when compared with the SUMOMut cells. These genes demonstrated a shift towards muscle cell
differentiation (Tables S1 and S2).
Further analysis revealed that 169 DEGs were down-regulated in both DBDMut and SUMOMut cells when
compared with the WT. By referring to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
database, the focal adhesion pathway was the only one significantly (p value < 0.05) enriched (Table S2).
Representative genes encoded proteins for the basement membrane (laminin subunit beta 3), actin bind-
ing (filamin A and actinin alpha 4), and ECM binding (collagen type VI alpha 3 chain and talin 1) (Figures 4D
and 4E and Table S1). There were also 74 DEGs up-regulated in both the DBD Mut and SUMO Mut cells;
however, no pathway was significantly enriched. Therefore focal adhesion alterations in both DBDMut and
SUMO Mut cells probably contributed to hepatoblast and hepatocyte formation.
Proteomic Analysis of WT and HNF4a-Edited Hepatic Progenitor Stage Cells
Following on from the metabolic and transcriptomic studies, we examined alterations in the proteome at dif-
ferentiation day 9 from WT, DBD Mut, and SUMO Mut lines. Tryptic peptides were analyzed by LC-MS/MS,
and the raw MS output data was processed using the MaxQuant platform and then analyzed in Perseus soft-
ware (Tyanova et al., 2015, 2016). A total of 3,639 protein groups were evaluated across all cell types. PCA anal-
ysis showed that the DBD Mut cells were distinct from the WT and SUMO Mut cells (Figure 5A and S5A).
Proteins with reduced expression unique to the DBD Mut cells (Table S3), compared with WT, were involved
in metabolic processes and oxidative phosphorylation (Figure 5B and Table S4). Notably, 119 of the 486 less
abundant proteins specifically in the DBDMut cells were mitochondrial proteins (Table S3). A number of sub-
units of Complexes I, II, III, IV, and V from the respiratory electron transport chain were down-regulated in the
DBDMut cells (Figure 5B). These included the core subunits of Complex I NADHdehydrogenase [ubiquinone]
flavoprotein 1 and 2 (NDUFV1 and NDUFV2) and NADH dehydrogenase [ubiquinone] iron-sulfur protein 3
(NDUFS3) (Figure 5B and Table S3). In addition, the most down-regulated proteins in the DBD Mut included
mitochondrial HMGCS2 and glycine dehydrogenase (GLDC) (Table S3). HMGCS2 catalyzes the first step of
ketogenesis, whereas GLDC is involved in glycine degradation. The decreased expression of HMGCS2 and
GLDC was consistent at the mRNA level, together with other metabolic enzymes such as glutamate dehydro-
genase 1 (GLUD1) and aldehyde dehydrogenase 5 family member A1 (ALDH5A1) (Figures 4E and S5B). Taken
together, the HNF4a DBD domain is essential to mitochondrial function and cellular metabolism.
Proteins detected at reduced levels in the SUMO Mut cells were significantly enriched for ECM orga-
nization and lipoprotein metabolic pathways (Figure 5C and Table S4). A dense network of associations
was found around heparan sulfate proteoglycan 2 (HSPG2) in STRING, which is a web resource of
known and predicted protein-protein interactions (Szklarczyk et al., 2015). HSPG2 encodes the perlecan
protein, a core component of basement membranes. HSPG2 formed strong associations with the
thyroid hormone transporter TTR, apolipoproteins APOA2 and APOA4, and the endocytic receptor
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low-density lipoprotein receptor-related protein 2 (LRP2), the basement membrane protein nidogen-
1(NID1), ECM proteins laminin subunit alpha-1 (LAMA1) and versican (VCAN), and the alpha chain of
the coagulation factor fibrinogen (FGA) (Figure 5C). Proteins that were more abundant in the SUMO
Mut cells were mostly involved in the regulation of protein localization to Cajal body and telomeres
(Figure 5C and Table S4). A dense network of associations was also formed by chaperonin-containing
T-complex subunits (CCT1-8) (Figure 5C). Of note, SUMO Mut cells also contained differentially ex-
pressed proteins that were significantly altered for by at least 8-fold (Table S3). These proteins were
involved in diverse cellular processes, including gluconeogenesis and TCA cycle flux (phosphoenolpyr-
uvate carboxykinase 2 [PCK2]), as well as microRNA transport (Exportin 5). This suggested that the
introduced point mutations in HNF4a not only affected ECM organization and cellular metabolism
but also led to defects in miRNA transport.
There were 27 commonly down-regulated proteins in the DBD Mut and SUMO Mut cells when compared
with the WT control. These proteins were most enriched in KEGG pathways such as complement and
coagulation cascades, ECM-receptor interaction, pyruvate metabolism, and TCA cycle (Table S4). The
Figure 5. Proteomic Analysis of Hepatic Progenitor Stage Cells from WT and HNF4a Genome-Edited Pluripotent Stem Cells
(A) Principal component analysis of the WT, DBD Mut, and SUMO Mut cells at hepatic progenitor stage (n = 4 replicates).
(B) Top five enriched biological processes of the significantly down-regulated proteins specifically in the DBD Mut cells and the representative down-
regulated mitochondrial proteins in the DBD Mut cells. Pathway enrichment was analyzed using Enrichr server.
(C) Top five enriched biological processes and the protein-protein interaction networks of the significantly down- or up-regulated proteins in the SUMOMut
cells compared with the WT. Pathway enrichment was analyzed using Enrichr server. The protein-protein interaction networks were generated on STRING
server. Network nodes represent proteins, and edges represent protein-protein associations. The bolder the edge, the higher the confidence.
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representative proteins included pyruvate carboxylase (PC) and PCK2 (Figure S5C), which are involved in
gluconeogenesis, pyruvate metabolism, and TCA cycle flux, supporting our metabolomic analysis.
Integrating Transcriptomics and Proteomics Datasets
To integrate information from both transcriptomics and proteomics experiments, we re-analyzed both da-
tasets for the edited cells (DBDMut/WT and SUMOMut/WT) using a free web-based multiomics data visu-
alization application named PaintOmics 3 (http://bioinfo.cipf.es/paintomics/) (Hernandez-de-Diego et al.,
2018). In the DBD Mut cells, the most enriched KEGG pathway was cholesterol metabolism, followed by
pathways in peroxisome proliferator-activated receptor signaling, ECM-receptor interaction, focal adhe-
sion, and amino acid metabolism. Five of the top 10 enriched pathways in the DBD Mut cells were also
in the top 10 significantly enriched pathways in the SUMO Mut cells. They were cholesterol metabolism,
complement and coagulation cascades, ECM-receptor interaction, focal adhesion, and cell adhesion mol-
ecules (Figure 6A). Based on these analyses, we summed up the representative proteins that were signif-
icantly altered in the DBD Mut cells and in both DBD Mut and SUMO Mut cells (Figure 6B and Table S3).
Taken together, the DBD Mut and SUMO Mut cells shared similar dysregulated genes and proteins that
function in cellular metabolism and cell-ECM interaction. Meanwhile, the DBDMut cells had disrupted res-
piratory electron transport chain and metabolism, highlighting the importance of the HNF4a DBD domain.
A
B
Figure 6. Integrated Transcriptomic and Proteomic Analysis of Hepatic Progenitor Stage Cells Differentiated from WT and HNF4a Genome-
Edited Pluripotent Stem Cells
(A) Top 10 enriched KEGG pathways in the DBD Mut cells or in the SUMO Mut cells from the overlayered analysis of both transcriptomic and proteomic
datasets.
(B) Representative proteins and their fold changes in expression in the DBD Mut and SUMO Mut cells when compared with WT cells. The label-free
quantification intensities have been log10 transformed.
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DISCUSSION
The hepatocyte nuclear factor network is vital for mammalian liver development and organ homeostasis
(Odom et al., 2006; Watt et al., 2003). This network controls the expression of a large number of hepatic
genes, which perform a broad range of functions (Battle et al., 2006; Bolotin et al., 2010; Odom et al.,
2004). In the present study, we investigated HNF4a function during hepatic specification from human
pluripotent stem cells. Without its DNA-binding domain, the truncated form of HNF4a failed to make he-
patic progenitor cells, and displayed disruption in key processes such as the respiratory electron transport
chain and cellular metabolism. Conversely, the introduction of point mutations, in the C-terminal SUMO
consensus motif of HNF4a permitted hepatic progenitor commitment, but led to failed hepatocyte spec-
ification. Key genes involved in metabolism, TCA cycle flux, miRNA transport, cell-ECM interactions, mRNA
processing, and coagulation cascades were implicated in this study.
Pluripotent stem cells rely heavily on aerobic glycolysis during self-renewal, but they switch quickly
to oxidative phosphorylation (OXPHOS) during mesoderm and endoderm differentiation to meet
the energy demand. Interestingly, during hepatic differentiation from human pluripotent stem cells,
OXPHOS has been reported to decrease when cells reach the hepatic progenitor stage, followed by an in-
crease during hepatocyte maturation (Hopkinson et al., 2017; Jing et al., 2018). In our study, we integrated
omics analyses at the hepatic progenitor stage and found that ketogenesis, amino acid metabolism,
TCA flux, and cholesterol metabolism pathways were largely down-regulated in mutated cells. We propose
that these alterations were contributory factors that led to failed hepatocyte specification.
Previous studies in rodents have also shown that HNF4a-null embryonic livers display defects in glycogen
synthesis (Parviz et al., 2003). In addition, glucose responsiveness was abolished in murine embryoid-body-
derived visceral endoderm when HNF4a was deleted (Stoffel and Duncan, 1997). In this study, we demon-
strate that HNF4a is critical to glucose utilization at the hepatic progenitor stage (Figure 3A). When HNF4a
was truncated or point mutated, glucose and pyruvate utilization were compromised (Figures 3A and S3).
Similarly, PC and PCK2, key enzymes in pyruvate cycling, were significantly down-regulated in genome-
edited cells (Figure 6B). Notably, the SUMO Mut cells showed more pronounced metabolomic changes
than the DBD Mut cells (Figure 3). The reason behind this is unknown, but it could be that the knockin mu-
tations affected HNF4a0s second transactivation domain (AD-2) leading to alterations in gene transcription.
Although the liver is regarded as one of the body’s metabolic centers, less is known about the amino acid
metabolism dynamics during early hepatogenesis. A recent study reported that L-valine is essential to mu-
rine liver bud growth and promotes the propagation of human hepatic progenitor organoids (Koike et al.,
2017). This study did not investigate whether valine was required for human liver bud formation, but we
note that valine consumption was significantly reduced in both DBDMut and SUMOMut cells at the hepat-
ic progenitor stage. Although valine was not essential for hepatoblast specification in SUMOMut cells, it is
possible that valine was required for the specification of bipotent hepatic progenitors. However, further
research is required to test this hypothesis.
Cell-ECM interaction also play a critical role in cellular differentiation. In the DBD Mut and SUMO Mut he-
patic progenitor stage cells, we identified commonly down-regulated genes. They were enriched for focal
adhesion and ECM organization pathways (Figures 4 and 6, Supplemental Information, Tables S2 and S4).
Specific to the SUMOMut cells, exportin-5 (XPO5) expression was reduced, potentially affecting precursor
miRNA transport from the nucleus to the cytoplasm. We also observed down-regulation of genes that
regulate gene transcription and mRNA processing, such as FOXC1, FOXO3 (Figure 4D), and small nuclear
ribonucleoprotein G (SNRPG) (Supplemental Information, Table S3). We believe that these data point to
deficiencies in multiple cell biological processes that are instrumental in the hepatoblast to hepatocyte
transition.
In summary, this study highlights the important role played by HNF4a during hepatic endoderm differen-
tiation. System biology analyses revealed numerous potential regulatory functions for HNF4a. Those
include the control of the respiratory electron transport chain, cell metabolism, pyruvate cycling, TCA cycle
flux, miRNA transport, mRNA processing, and cell-ECM interaction.
Limitations of the Study
This study was based on an in vitro-directed differentiation system and was not tested in vivo.
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METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.05.028.
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Supplemental Figure 1 
Figure S1. Related to Figure 2, Differentiation towards the definitive endoderm was not affected in 
SUMO Mut cells, but was in DBD Mut cells. 
(A) Immunostaining of SOX17 in WT, DBD Mut and SUMO Mut pluripotent stem cells differentiated 
toward definitive endoderm. Scale bar = 50 um.  
(B) The expression levels of SOX17 and FOXA2 during hepatic differentiation. Data were normalized to 
the housekeeping gene ACTB and expressed relative to day 0 cells. The results shown represent three 
biological replicates and error bars represent SD. **p < 0.01, *** p < 0.001, **** p < 0.0001; two-way 
ANOVA with Tukey post hoc test.    
(C) Real-time PCR quantification of AFP and CEBPA mRNA level. Data were normalized to the 
housekeeping gene ACTB and expressed relative to the WT cells. The results shown represent three 
biological replicates and error bars represent SD. **p < 0.01, *** p < 0.001, **** p < 0.0001; one-way 
ANOVA with Tukey post hoc test.    
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Supplemental Figure 2 
Figure S2. Related to Figure 2B, Exons 2 and 3 were skipped in HNF4a DBD Mut cells. 
Sequencing of HNF4a cDNA in the DBD Mut cells at hepatic progenitor stage showed exon 2 and 3 
were skipped.  
 
 
 
Supplemental Figure 3 
Figure S3. Related to Figure 3, Amino acid metabolism was disrupted in the DBD Mut and SUMO 
Mut hepatoblasts. 
Consumption and production rates of essential amino acids (isoleucine and lysine) and non-essential 
amino acids (alanine, glutamine, glutamate, glycine, tyrosine and t-methylhistadine) in WT, DBD Mut 
and SUMO Mut cells at day 9 in differentiation. Data represent three biological replicates and error 
bars represent SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; one-way ANOVA with Tukey 
post hoc test.    
 
 
 
Supplemental Figure 4  
Figure S4. Related to Figure 4, Heat map representation of the 100 genes with highest variance in 
WT, DBD Mut and SUMO Mut cells at the hepatic progenitor stage. 
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Supplemental Figure 5 
Figure S5. Related to Figure 5, Heat map representation of the proteomics dataset and the 
expression of representative metabolic enzymes. 
(A) Heat map of proteomics analysis of the WT, DBD Mut and SUMO Mut cells at the hepatic 
progenitor stage. The LFQ intensities were log10 transformed, then z-scored and normalized by row. 
(B) The expression of metabolic enzymes GLDC, GLUD1 and ALDH5A1 at mRNA level in the progenitor 
stage cells. Data were normalized to the housekeeping gene ACTB and expressed relative to the WT 
cells. The results shown represent three biological replicates and error bars represent SD. **p < 0.01, 
*** p < 0.001, **** p < 0.0001; one-way ANOVA with Tukey post hoc test. (C) The expression of PC 
and PCK2 throughout hepatic differentiation process. Data were normalized to the housekeeping gene 
ACTB and expressed relative to day 0 cells. The results shown represent three biological replicates and 
error bars represent SD. **p < 0.01, *** p < 0.001, **** p < 0.0001; two-way ANOVA with Tukey post 
hoc test.    
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gRNA name Sequence (5’-3’) 
HNF4a-KO-g1-F caccGCTAGAGAAAGCTGGGGCTCG 
HNF4a-KO-g1-R aaacCGAGCCCCAGCTTTCTCTAGC 
HNF4a-KO-g2-F caccGAACCTGGCCACCTTCTGGGG 
HNF4a-KO-g2-R aaacCCCCAGAAGGTGGCCAGGTTC 
HNF4a-KO-g3-F caccGCCCAGAGACAGCTGCCCTTC 
HNF4a-KO-g3-R aaacGAAGGGCAGCTGTCTCTGGGC 
HNF4a-KO-g4-F caccGTCAGGGAGAAGACAGACCTT 
HNF4a-KO-g4-R aaacAAGGTCTGTCTTCTCCCTGAC 
HNF4a-Kin-g11-F caccGTGCAACAGGTTGTCAATCT 
HNF4a-Kin-g11-R aaacAGATTGACAACCTGTTGCAC 
HNF4a-Kin-g12-F caccGGGAGGTCCGTGCCAAGCCC 
HNF4a-Kin-g12-R aaacGGGCTTGGCACGGACCTCCC 
  
Name Sequence (5’-3’) 
5-HA-F gagctcgtttaaacggcgcgccGCTTGAACCCAGGAGGCA 
5-HA-R gcaatatttcaagaatgcaTAAACTGAATCTGCTCGATCATCTG 
3-HA-F gattatctttctagggttaacGCTCTTCGGCATGGCTAG 
3-HA-R cggcccggccttaattaaTCTCAGGAATCTGCAATTCAC 
 
Table S5. Related to Figure 1, gRNA names and sequences (top panel) and primer names 
and sequences used in Gibson assembly.   
 
Name Sequence (5’-3’) 
T7E1-KO-F CCTGGTCCCTTGGCAAGAACT 
T7E1-KO-R AAGACGGGCTCATCTACTGAGGC 
T7E1-Kin-F TTGCCCACCCTCTTCCATTGT  
T7E1-Kin-R CACTTCAGAGAGGTCTCCTGTGGC 
  
Name Sequence (5’-3’) 
targeting-LA-F1 CTATGCATGGTGCTAGGTGG 
targeting-LA-R1 CATTTTGACTCACGCGGTCG 
targeting-LA-R2 TCTCAGGAATCTGCAATTCACTC 
targeting-RA-F1 CAGGTGCAGGTGAGCTTGGAGG 
targeting-RA-F2 CAGACCGATAAAACACATGCG 
targeting-RA-R1 GGATCTCTGAGGTCACCCCTCACTAC 
 
Table S6. Related to Figure 1, Primer names and sequences (top panel) used in T7EI assay 
and primer names and sequences used in screening of knock-in clones.   
 
 
Immunostaining 
Antibody Name Host Dilution Supplier 
Primary antibodies       
OCT4 Rabbit Poly 1/200 Abcam 
NANOG Goat Poly 1/200 Abcam 
AFP Mouse Mono 1/500 Abcam 
SOX17 Goat Poly 1/500 R & D Systems 
HNF4a Rabbit Poly 1/100 Santa Cruz 
IgG Mouse 1/400 DAKO 
IgG Rabbit 1/400 DAKO 
IgG Goat 1/400 DAKO 
Secondary antibodies       
Anti-Mouse 488 Rabbit 1/400 Life Technologies 
Anti-Mouse 568 Goat 1/400 Life Technologies 
Anti-Rabbit 488 Donkey 1/400 Life Technologies 
Anti-Rabbit 568 Donkey 1/400 Life Technologies 
Anti-Goat 488 Rabbit 1/400 Life Technologies 
Anti-Goat 568 Rabbit 1/400 Life Technologies 
 
Flow Antibody Conjugated Type Dilution Supplier 
SSEA-1 FITC Mouse IgM 1/50 Biolegend 
SSEA-4 PE Mouse IgG 1/50 Biolegend 
TRA-1-60 PE Mouse IgM 1/50 Biolegend 
 
Western Blot Antibody Host Dilution Supplier 
Primary antibodies       
HNF4a Rabbit Ploy 1/1000 Santa Cruz 
b-actin Mouse Mono 1/10000 Sigma 
Secondary antibodies       
Anti-Rabbit IgG HRP Swine 1/3000 R & D Systems 
Anti-Mouse IgG HRP Goat 1/3000 R & D Systems 
 
Table S7. Related to Figure 1 and 2, Optimised antibody concentrations used in 
immunostaining, flow cytometry and western blotting.  
 
 
 
 
Gene name Probe number 
HNF4a Hs01023298_m1 
HNF1a Hs00167041_m1 
TTR Hs00174914_m1 
APOA2 Hs00155788_m1 
APOA4 Hs00166636_m1 
HMGCS1 Hs00266810_m1 
HMGCS2 Hs00985427_m1 
LAMB3 Hs00165078_m1 
FGA Hs00241027_m1 
FOXA2 Hs00232764_m1 
SOX17 Hs00751752_s1 
AFP Hs01040607_m1 
CEBPA Hs00269972_s1 
GLDC Hs01580591_m1 
GLUD1 Hs03989560_s1 
ALDH5A1 Hs00542449_m1 
PC Hs00559398_m1 
PCK2 Hs00356436_m1 
ACTB Hs01060665_g1 
 
Table S8. Related to Figure 2 and 4, TaqMan probes used in qPCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRANSPARENT METHODS 
 
Detailed methods are provided in the online version of this paper and include the following: 
• KEY RESOURCES TABLE 
• CONTACT FOR REAGENTS AND SOURCE SHARING 
• EXPERIMENTAL MODEL AND SUBJECT DETAILS 
o Cell lines 
o Cell Culture Conditions 
o Hepatocyte Differentiation System 
 
• METHOD DETAILS 
o CRISPR/Cas9n-sgRNA expression plasmids and targeting vector construction 
o Nucleofection of H9 cells 
o Selection of the nucleofected cells 
o Genotyping the single cell-derived colonies 
o Removal of the transposon in the HNF4a point mutation knock-in experiment 
o Immunostaining 
o Flow cytometry 
o Western blotting 
o ELISA quantification 
o CYP3A assay 
o 1H NMR-based metabolomics analysis 
o Microarray analysis 
o Label-free LC-MS/MS proteomics analysis 
• QUANTIFICATION AND STATISTICAL ANALYSIS 
o Metabolomics data analysis 
o Microarray data processing and visualization 
o Gene set enrichment analysis (Gene Ontology) 
o Label-free proteomics data analysis 
o Visualization of over-layered analysis of microarray and proteomics datasets   
• DATA AND SOFTWARE AVAILABILITY 
 
KEY RESOURCES TABLE 
 
REAGENTS or 
RESOURCES 
SOURCE IDENTIFIER 
Antibodies   
Human NANOG 
antibody 
R&D systems AF1997 
Human OCT4 
antibody 
Abcam AB19857 
Human SOX17 
antibody 
R&D systems AF1924 
Anti-Human 
SSEA4 PE 
eBioscience 12-8843-42 
Anti-Human 
CD15(SSEA1) 
FITC 
eBioscience 11-0159-42 
Anti-Human 
TRA-1-60 PE 
eBioscience 12-8863-82 
HNF4a (H-171) SantaCruz Sc-8987 
Monoclonal anti-
AFP antibody 
Sigma A8452 
Monoclonal anti-
b-ACTIN 
R&D systems A5441 
Mouse IgM 
isotype control 
FITC 
eBioscience 11-4752-80 
Mouse IgG3 
isotype control 
PE 
eBioscience 12-4742-41 
Polyclonal Swine 
Anti-Rabbit 
Immunoglobulin
s HRP 
DAKO P0399 
Polyclonal Goat 
Anti-Mouse 
Immunoglobulin
s HRP 
DAKO P0447 
Donkey anti-
Goat IgG (H+L) 
Cross-Adsorbed, 
Alexa Fluor® 568 
Thermo 
Fisher 
Scientific 
A11057 
Goat anti-Rabbit 
IgG (H+L) Cross-
Adsorbed, Alexa 
Fluor® 488 
Thermo 
Fisher 
Scientific 
A11008 
Donkey anti-
Mouse IgG (H+L) 
Highly Cross-
Adsorbed, Alexa 
Fluor® 488 
Thermo 
Fisher 
Scientific 
A21202 
4ʹ,6-Diamidine-
2ʹ-phenylindole 
dihydrochloride 
(DAPI) 
Roche 10236276001 
Mouse IgG Vector 
Laboratories 
I-2000 
Rabbit IgG Vector 
Laboratories 
I-1000 
Goat IgG Vector 
Laboratories 
I-5000 
Bacterial and 
Virus Strains 
  
One Shot TOP10 
Chemically 
Competent E. 
coli 
Thermo 
Fisher 
Scientific 
C404003 
One Shot Stbl3 
chemically 
competent E.coli 
Thermo 
Fisher 
Scientific 
C7373-03 
Plasmid 
Constructs 
  
pSpCas9n(BB)-
2A-Puro (PX462) 
Addgene PX462 
pMCS-AAT_PB-
PGKpuroTK 
Wellcome 
Trust Sanger 
Institute 
N/A 
pCMV-hyPBase Wellcome 
Trust Sanger 
Institute 
N/A 
pMD19-T vector Takara 3271 
Chemicals, 
Peptides, and 
Recombinant 
Proteins 
  
Matrigel matrix Corning 354248 
Human 
Recombinant 
Laminin 521 
BioLamina LN521 
Human 
Recombinant 
Laminin 111 
BioLamina LN111 
Recombinant 
Human/Murine/
Rat Activin A 
(E.coli derived) 
Peprotech 120-14E 
Recombinant 
Mouse Wnt-3a 
Protein 
R&D systems 1324-WN/CF 
Recombinant 
Human HGF 
Peprotech 100-39 
Recombinant 
Human 
Oncostatin M 
Peprotech 300-10 
B27 minus 
vitamin A 
Thermo 
Fisher 
Scientific 
12587-010 
RPMI 1640 Thermo 
Fisher 
Scientific 
11875-093 
Penicillin-
Streptomycin 
Thermo 
Fisher 
Scientific 
15140-122 
Knockout DMEM Thermo 
Fisher 
Scientific 
10829-018 
Knockout serum 
replacement 
Thermo 
Fisher 
Scientific 
10828-028 
GlutaMAX Thermo 
Fisher 
Scientific 
35050-038 
NEAA Thermo 
Fisher 
Scientific 
11140-035 
DMSO Honeywell 
Chemicals 
D5879 
Beta-
mecaptoethanol 
Thermo 
Fisher 
Scientific 
31350-010 
HepatoZYME-
SFM 
Thermo 
Fisher 
Scientific 
17705-021 
Hydrocortisone- 
21 
hemisuccinate 
sodium salt 
Sigma H4881 
mTeSR1 medium Stem Cell 
Technologies 
85850 
Gentle Cell 
Dissociation 
Reagent 
Stem Cell 
Technologies 
07174 
TrypLE Express 
Enzyme 
Thermo 
Fisher 
Scientific 
12604013 
Y-27632 
(Dihydrochloride
) 
Millipore SCM075 
DPBS  Thermo 
Fisher 
Scientific 
14190144 
DPBS with 
calcium and 
magnesium 
Thermo 
Fisher 
Scientific 
14040133 
Bovine Serum 
Albumin 
Sigma A7906-10G 
OneComp 
eBeads 100 tests 
eBioscience 01-1111-42 
Trypan Blue 
Solution, 0.4% 
Thermo 
Fisher 
Scientific 
15250061 
NuPAGE 4-12% 
Bis-Tris Protein 
Gels, 1.5mm, 10-
well 
Thermo 
Fisher 
Scientific 
NP0335BOX 
NuPAGE MES 
SDS Running 
Buffer (20x) 
Life 
Technologies 
NP0002 
NuPAGE Transfer 
Buffer (20x) 
Life 
Technologies 
NP0006-1 
NuPAGE LDS 
Sample Buffer 
Thermo 
Fisher 
Scientific 
NP0007 
SeeBlue Plus 2 
Prestained 
Standard 
Thermo 
Fisher 
Scientific 
LC5925 
TWEEN 20 Sigma T2700-100ML 
Phosphate 
buffered saline 
tablet 
Sigma P4417-100TAB 
SYBR Safe DNA 
gel stain 
Life 
Technologies 
S33102 
UltraPure 
Agarose 
Life 
Technologies 
16500-100 
DNA ladder, 1 kb New England 
BioLabs 
N3232S 
UltraPure 
DNase/RNase-
free distilled 
water 
Life 
Technologies 
10977-023 
Ampicillin Sigma A9518-5G 
SOC medium New England 
BioLabs 
B9020S 
LB medium Sigma L3022 
LB agar medium Sigma L2897 
FIAU Moravek M251 
Puromycin 
dihydrochloride 
Life 
Technologies 
A11138-03 
FastDigest BbsI 
(BpiI) 
Fermentas/T
hermo 
Scientific 
FD1014 
DTT Fermentas/T
hermo 
Scientific 
R0862 
T4 DNA ligase 
and buffer 
New England 
BioLabs 
M0202S 
T4 
polynucleotide 
kinase 
New England 
BioLabs 
M0201S 
Adenosine 5ʹ-
triphosphate, 10 
mM 
New England 
BioLabs 
P0756S 
Q5 High-Fidelity 
DNA 
Polymerases 
New England 
BioLabs 
M0491 
T7 
endonuclease I 
(T7EI) 
New England 
BioLabs 
M0302S 
NsiI-HF New England 
BioLabs 
R3127S 
AscI New England 
BioLabs 
R0558S 
HpaI New England 
BioLabs 
R0105S 
PacI New England 
BioLabs 
R0547S 
TRIzol Reagent Thermo 
Fisher 
Scientific 
15596026 
Critical 
Commercial 
Assays 
  
Human stem 
cell 
Nucleofector kit 
1 
Lonza VPH-5012 
P450-Glo™ 
CYP3A4 Assay 
System 
Promega V8902 
Human Alpha 
Fetoprotein 
(AFP) ELISA Kit, 
96 tests 
Alpha 
Diagnostic 
0500 
Human Serum 
Albumin ELISA 
Kit, 96 tests 
Alpha 
Diagnostic 
1190 
GenElute 
Mammalian 
Genomic DNA 
miniprep Kit 
Sigma G1N70-1KT 
Pierce BCA 
Protein Assay 
Kit 
Thermo 
Fisher 
Scientific 
23225 
SuperSignal 
West Pico 
Chemiluminesce
nt Substrate 
Thermo 
Fisher 
Scientific 
34077 
QIAprep spin 
miniprep kit 
Qiagen 27106 
QIAquick gel 
extraction kit 
Qiagen 28704 
GeneChip 
Human Genome 
HG-U133 Plus 
2.0 Array 
Affymetrix N/A 
Experimental 
Models: Cell 
Lines 
  
H9 female 
human ESCs 
WiCell WA09 
H9 with HNF4a 
truncated 
This study N/A 
H9 with HNF4a 
point mutated 
This study N/A 
Oligonucleotide
s 
  
See Table S5, S6 N/A N/A 
Recombinant 
DNA 
  
gRNA for CRISPR 
cloned in 
SpCas9n(px462), 
see Table S5 for 
oligonucleotide 
sequences 
This study N/A 
PB_HNF4a_PGK
puroTK 
This study N/A 
Software and 
Algorithms 
  
Flowjo FLOWJO, LLC https://www.flowjo.com/ 
FACSDIVA 
software 
BD 
Biosciences 
N/A 
GraphPad Prism GraphPad 
Software 
https://www.graphpad.com/scientific 
software/prism/ 
Columbus Image 
Data Storage 
and Analysis 
System 
PerkinElmer http://www.cambridgesoft.com/ensemble/spotfire/C
olumbus/default.aspx 
Chenomx NMR 
Suite version 8.1 
Chenomx https://www.chenomx.com/software/archive/ 
Microarray Suite 
software 
 
Affymetrix N/A 
Limma packages Bioconductor https://bioconductor.org/packages/ 
release/bioc/html/limma.html 
MaxQuant 
proteomics 
software 
Max Planck 
Institute of 
Biochemistry 
http://www.biochem.mpg.de/5111795/maxquant 
Perseus 
proteomics 
software 
Max Planck 
Institute of 
Biochemistry 
http://www.biochem.mpg.de/5111810/perseus 
Enrichr analysis 
website 
Icahn School 
of Medicine 
at Mount 
Sinai 
 
http://amp.pharm.mssm.edu/Enrichr/ 
STRING protein 
interaction 
analysis website 
N/A https://string-db.org 
PaintOmics3 N/A http://bioinfo.cipf.es/paintomics/ 
 
 
CONTACT FOR REAGENTS AND SOURCE SHARING 
 
Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact, David C. Hay (davehay@talktalk.net). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Cell lines 
H9 female human ESCs were purchased from WiCell. Cells were routinely checked for cell 
surface markers using flow cytometry and for the presence of mycoplasma.  
 
Cell Culture Conditions 
H9 human ESCs and genome modified DBD Mut and SUMO Mut cell lines were cultured on 
Matrigel coated cell culture plates with mTeSR1 medium. Cells were routinely split in 1:3 ratio 
using Gentle Cell Dissociation reagent. For nucleofection, single cells were obtained by 
treating the cells with Gentle Cell Dissociation reagent for 7-8 minutes at 37 oC. ROCK inhibitor 
was used to maintain the single cells. 
 
Hepatocyte Differentiation System 
Hepatocyte differentiation of the different cell lines was carried out following lab-developed 
protocol (Wang et al., 2017). Briefly, 5.5-6.5x105 single cells were seeded into per well on 6-
well plates coated with LN521/LN111 mix (1:3) for differentiation. Once cells reached 
approximately 40% confluency post seeding, hepatocyte differentiation was initiated by 
switching the mTeSR1 medium to RPMI 1640 medium supplemented with 2 % B27 (minus 
Vitamin A), 100 ng/ml Activin A and 50 ng/ml Wnt 3a. This definitive endoderm induction 
medium was changed daily for 3 days. Subsequently, the differentiation medium was 
switched to Knockout DMEM medium supplemented with 20 % knockout serum replacement, 
0.5 % GlutaMAX, 1% NEAA and DMSO, and 0.1 mM beta mecaptoethanol. This hepatic 
progenitor specification medium was changed daily for 5 days. Following this, the 
differentiation medium was changed to HepatoZYME medium supplemented with 1 % 
GlutaMAX, 10 uM hydrocortisone, 20 ng/ml hepatocyte growth factor (HGF) and 10 ng/ml 
oncostatin M (OSM). This hepatocyte-like cells maturation medium was changed every other 
day for 10 days. The derived hepatocyte-like cells were checked for functions, including basal 
cytochrome P450 3A activity, albumin and AFP secretion. In addition, cells at representative 
time points (day 0, day 3, day 9 and day 18) were routinely checked for the expression of 
typical markers corresponding to that time point.        
 
METHOD DETAILS 
 
CRISPR/Cas9n-sgRNA expression plasmids and targeting vector construction 
Oligonucleotides for gRNAs (Table S5) targeting HNF4a were annealed and cloned into a BbsI 
digested Cas9n backbone plasmid (PX462) following a published protocol (Ran et al., 2013). 
 
The construction of the piggyBac-based targeting construct involved three main steps: the 
amplification of the 5’-homology arm (HA) and the 3’-HA; the insertion of the 5’-HA into the 
backbone plasmid; and the insertion of the 3’-HA into the backbone plasmid.  
 
The PCR primers for amplifying 5’-HA and 3’-HA used in Gibson assembly were generated 
using NEBuilder (https://nebuilder.neb.com) (Table S5). The desired point mutations were 
incorporated into the primers. The PCR amplification of the two homology arms were 
catalysed by Q5 high-fidelity DNA polymerase (New England Biolabs). H9 genomic DNA was 
used as the template for the PCR. The amplified homology arms were then purified before 
being inserted into the backbone plasmid.  
 
The used piggyBac backbone was a kind gift of Dr. Kosuke Yusa from the Wellcome Trust 
Sanger Institute, UK. For the insertion of the 5’-HA, the backbone plasmid was digested using 
NsiI and AscI enzymes and then gel purified. The purified 5’-HA was then inserted using a 
Gibson assembly reaction. The piggyBac-5’-HA plasmid was then purified and sequenced to 
confirm the correct insertion of the 5’-HA. Following this, the piggyBac-5’-HA plasmid was 
digested using HpaI and PacI enzymes and then purified, the 3’-HA was then inserted into the 
backbone and completed the construction of the donor plasmid. Sequencing was also 
performed to confirm the correct insertion of the 3’-HA.  
 
Nucleofection of H9 cells 
H9 cells at 70-80 % confluency were dissociated using Gentle Cell Dissociation reagent to 
make single cell suspension. For HNF4a gene knockout, ~ 0.8 million live cells were 
nucleofected with 3 µg of each Cas9n-sgRNA expression plasmid. For the knockin experiment, 
~ 0.8 million cells were nucleofected with 5 µg donor plasmid and 3 µg of both Cas9n-sgRNA 
expression plasmids. The Human Stem Cell Nucleofector® Kit 1 (Lonza) was used and the 
nucleofection was facilitated by a Nucleofector 2b device with program A-023 (Lonza). 
 
Selection of the nucleofected cells 
48 hours post nucleofection, the cells were selected using 0.5 µg/ml puromycin for 2 days. 
Puromycin-resistant cells were then propagated and passaged to 10-15 96-well plates at the 
concentration of 0.8 cell/well in mTeSR1 medium supplemented with 10 µM Rho-associated 
protein kinase (ROCK) inhibitor (Sigma-Aldrich). At this point, puromycin in the medium for 
HNF4a knockout experiment cells was removed, but it was kept for selecting cells for 
HNF4a  point mutation knock-in experiment. Following the seeding, the cells were 
maintained at 37 oC with 10 % CO2 for 7 days to form single cell-derived colonies.  
 
The single-cell derived colonies were picked at about another 5 days later and passaged at a 
1:2 ratio to two different plates. ~4 days after the passaging, cells on one plate were lysed for 
genomic DNA extraction. 
 
Genotyping the single cell-derived colonies 
Colonies from HNF4a knockout experiments were analysed using T7EI assay (Table S6). The 
targeted region was PCR amplified and the PCR products were then digested using T7EI 
enzyme, and subsequently separated on agarose gels and the genotypes were ‘readable’ on 
the gel.  
 
Colonies from HNF4a point mutation knock-in experiments were amplified using three-
primer PCRs (Table S6) to differentiate genomic sequences and inserted sequences. The PCR 
products were separated on agarose gels and the genotype were ‘readable’ on the gel.    
 
For promising colonies from the DNA gel-based genotyping, the PCR products were purified 
and then inserted into a pMD19-T vector to form a stable plasmid for sequencing. The 
colonies with correct genotypes were then saved and expanded to form stable isogenic cell 
lines. 
 
Removal of the transposon in the HNF4a point mutation knock-in experiment 
The correctly targeted colonies were established and two were used for the removal of the 
selection cassette introduced by the transposon. Briefly, ~0.8 million cells were nucleofected 
with 5 µg hyperactive PBase (gift from Dr. Kosuke Yusa) and the cells were culture in mTeSR1 
medium without puromycin. The cells were then maintained for 3-4 passages before the 
negative selection mediated by the thymidine analog 1-(2-deoxy-2-fluoro-β-D-
arabinofuranosyl)-5-iodouracil (FIAU) at a concentration of 200 nM. About 2 weeks after the 
negative selection, single cell-derived colonies were picked and genotyped as described 
above.  
 
Immunostaining 
Cells were fixed in 100 % ice-cold methanol at -20 oC for 30 minutes. Post fixation, cells were 
washed three times with DPBS for 5 minutes at room temperature. The cells were 
subsequently blocked with PBS-0.1 % Tween (PBST) containing 10 % BSA for 1 hour at room 
temperature. After that, the blocking solution was removed and the respective primary 
antibody diluted in 1% BSA/PBST was added to the cells. The primary antibody was incubated 
at 4 oC overnight with gentle agitation. Following this, the used primary antibody solution was 
removed and the cells were washed three times with PBST for 5 minutes at room 
temperature. The cells were then incubated with the appropriate secondary antibody diluted 
in PBST for 1 hours at room temperature in the dark with gentle agitation. The cells were then 
washed three times with PBST. Following this, cells were stained with DAPI diluted in PBS 
(1:5000) for 2 minutes at room temperature. The DAPI solution was then removed and the 
cells were washed twice with PBST. In all cases, the stained cells were stored at 4 oC in the 
dark before imaging. The primary and secondary antibodies are listed in supplemental Table 
S7. 
 
All images were collected at room temperature using the automated Operetta fluorescent 
microscope. The images were processed using Columbus Image analysis server.  
 
Flow cytometry 
Fluorescence activated cell sorting (FACS) was used to confirm the expression of cell surface 
markers in hESCs. hESCs from a well on a 6-well plate were washed once with 2 ml DPBS and 
then dissociated with 1ml TrypLE. The cells were lifted off as single cells and collected. Post 
centrifugation, cells were resuspended in DPBS and filtered through a 0.22 µm filter. The 
single cell suspension was then incubated with the fluorochrome conjugated antibodies and 
the corresponding IgG controls for 30 minutes at 4 oC. The antibody information is listed in 
supplemental Table S7. Cells were then washed twice with DPBS, removing any unbound 
antibody, and span down at 200 x g for 5 minutes. Following this, cells were resuspended in 
300 µl of DPBS.  
 
Dead cells and debris were not included in the analysis. This was carried out by using an 
electronic live gate on forward scatter and side scatter parameters. Data for 20,000-50,000 
‘live’ events were acquired for each sample using a BD LSR Fortessa (4 laser) analyser. The 
data was analysed using FlowJo software.   
 
Western blotting 
Cells at different time points were washed once with DPBS and lysed in wells at room 
temperature in dark for 5 min. 200 µl home-made SUMO lysis buffer (2 % SDS, 50 mM Tris-
HCL (pH 8.0), 1 mM EDTA, 10 mM iodoacetamide) supplemented with proteinase and 
phosphatase inhibitors (Sigma-Aldrich) at 1 % final concentration was used for each well of a 
6-well plate. The cell extract was briefly sonicated using a Bioruptor (Diagenode) and span 
down for 15 min at 12,000 rpm at 4 oC. The protein supernatant was then transferred to a 
new 1.5 ml Eppendorf tube.    
 
The Pierce bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific) was used to quantify 
the protein concentration. Protein supernatant was diluted 1:10 using the lysis buffer. 20 µl 
protein supernatant of each sample was analysed in duplicates. Reagent A and B from the kit 
were mixed at a 1:50 ratio and a volume of 200 µl was transferred into each sample well. A 
standard curve was generated using the bovine serum albumin standards at concentrations 
ranging from 0-2000 µg/ml. The plate was incubated at room temperature for 30 min and the 
absorbance was read at 562 nm. The protein concentrations were calculated by linear 
extrapolation using the standard curve generated.  
 
The SDS-NuPAGE polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
proteins of different sizes. 50 μg protein supernatant was denatured at 100 oC for 10min in 1x 
NuPAGE LDS sample buffer supplemented with 10 mM DTT before being used for 
electrophoresis. 4-12 % Bis-Tris precast polyacrylamide gels (Thermo Fisher Scientific) were 
used with the XCell SureLock Mini-Cell System (Thermo Fisher Scientific) for the 
electrophoresis. Once the gel was fitted in the chamber, the tank was filled with 1x NuPAGE 
MES-SDS running buffer with 0.5 ml of NuPAGE Antioxidant (Thermo Fisher Scientific) added 
into the inner chamber. The samples were loaded along with a SeeBlue Plus 2 Pre-Stained 
Standard (Invitrogen). A current of 200 V was applied and the samples were run for 1-2 hours 
depending on the purpose of each experiment. The gels containing proteins were carefully 
removed from the cassette and were used in western blotting.  
 
Following the protein separation using SDS-PAGE gels, the proteins were then transferred 
from the gels to the Polyvinylidene fluoride (PVDF) membrane. The transfer sack was 
assembled in the following order from cathode to anode: 3x sponge; 2x filter paper soaked in 
1x NuPAGE Transfer Buffer; SDS-PAGE gel; PVDF membrane activated in 100 % ice-cold 
methanol; 2x filter paper soaked in 1x NuPAGE Transfer Buffer; 3x sponge. No bubbles 
between the gel and the membrane were allowed. Once the sack was assembled and placed 
into the XCell Blot II module, the module was then tightly sealed and placed into the transfer 
SureLock tank containing 1x transfer buffer in the inner chamber and ice-cold water in the 
outer chamber. The tank was then placed on ice for the entire protein transfer process. A 
constant current of 160mA was applied for 90-120 min.    
 
Once the proteins were successfully transfer onto the PVDF membrane, the membrane was 
blocked in 10 % skimmed milk at room temperature with gentle agitation for at least one hour 
to prevent non-specific antibody binding.  
 
Following this, the membrane was probed with desired primary antibody diluted in 5 ml 10 % 
BSA/PBST at 4 oC overnight with gentle rolling. The dilution ratios were optimised specifically 
for each primary antibody and were listed in Table 4. Unbound antibody was removed by 
three, 5-min washes with adequate 0.1 % PBST at room temperature with agitation. The 
primary antibody could be re-used for 2-3 times if stored at 4 oC properly.  
 
After probed with the primary antibody, the membrane was then incubated with 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibody diluted in 5 ml 
10 % skimmed milk at room temperature for at least one hour with gentle rolling. Unbound 
secondary antibody was then removed by three, 5-min washes with adequate 0.1 % PBST at 
room temperature with agitation. The primary and secondary antibody information is listed 
in supplemental Table S7. 
 
The proteins of interest were then detected using enhanced chemiluminescence (ECL). 
Proteins bands were visualised using the Pierce Enhanced Chemiluminescence Kit (Pierce, 
UK). Peroxidase buffer and the Luminol/Enhancer solution was mixed at a 1:1 ratio and spread 
evenly onto the membrane (2 ml for each membrane), followed by a 5-min incubation at 
room temperature. The HRP substrate reacts with the conjugated HRP group presented on 
the secondary antibody, specifying the target protein. The membrane was developed in the 
dark room using a film developer.   
 
ELISA quantification 
At the hepatocyte stage, day 18 cell culture supernatants were collected. Albumin and AFP 
concentration were determined using commercially available kits (Alpha Diagnostic Intl. Inc, 
San Antonio, USA). The ELISA assay was performed according to the manufacturer’s 
instructions with cell culture supernatants diluted at 1:3 (albumin) or 1:10 (AFP). After one 
hour incubation at room temperature, the wells were washed for four times and anti-human 
albumin or AFP HRP-conjugated secondary antibodies were added to the wells for 30 minutes. 
Subsequently, the wells were washed five times and the substrate was then added and 
incubated for a further 15 minutes in the dark at room temperature. Following this, the stop 
solution was added directly to the wells in order to stop the enzymatic reaction. The plates 
were then read at 450 nm with a reference wavelength of 630nm using a FLUOstart Omega 
plate reader (BMG LabTech, Germany). Blank cell culture media incubated at 37 oC for 48 
hours, diluted in 1:3 or 1:10 was used as a negative control. The data was then normalised to 
per ml per 48 hours per mg protein as determined by BCA assay (Pierce, UK).    
 
Quantitative real-time PCR 
Total RNA was collected from cells using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions. Total RNA was reverse transcribed using QuantiTect reverse-
transcription kit (Qiagen) following the manufacturer’s protocol. Real-time PCR was 
performed using TaqMan Fast Universal Master Mix and appropriate Taqman probes (Applied 
Biosystems). The primers are listed in supplemental Table S8. The samples were analysed 
using Roche LightCycler 480 Real-Time PCR System. Results were normalized to beta-actin. 
The qPCRs were run in triplicates.   
 
CYP3A assay 
Day 18 hESC-derived hepatocyte-like cells (HLCs) were incubated with the luciferin 
conjugated CYP3A (1:40) substrate (P450 P-Glo Luminescent Kit, Promega, UK) diluted in the 
maturation medium for 5 hours at 37 oC. Blank cell culture medium was used as a negative 
control. The supernatants were then collected and tested for luminescence. The luciferin 
detection reagent was reconstituted by mixing the buffer with the lyophilised luciferin 
detection reagent. 50 µl of the collected supernatant was mixed with 50 µl of the detection 
reagent in a white 96 well plate and incubated at room temperature in the dark for 20 
minutes. The relative levels of basal activity were measured using a luminometer (POLARstar 
optima). Units of activity were recorded as relative light units per ml per mg protein 
(RLU/ml/mg) as normalised by protein content.  
 
1H NMR-based metabolomics analysis 
24-hour cell culture medium from cells at differentiation day 9 was collected. The medium 
was then centrifuged at 4 oC, 300 x g for 5 min. The supernatant was collected and flash-
frozen on dry ice.  
 
All media samples were analysed on a 700 MHz Bruker Avance Neo NMR spectrometer 
equipped with a BBI room temperature probe.  The aliquots of the conditioned media from 
each cell line and unconditioned controls were thawed at room temperature and 550 µL of 
each was transferred into a microcentrifuge tube, to this 50 µL of deuterium oxide containing 
1 mM deuterated 3-(Trimethylsilyl)-1-propanesulfonic acid-d6 sodium (DSS-d6, 98% atom 
%D, Sigma-Aldrich), which was used as an internal reference for calibration, was added. The 
total volume of 600 µL was transferred into individually coded sample tubes in 96-racks 
(Bruker). 
 
Briefly, the samples were loaded using a SampleJet sample changer. The samples remained 
chilled at 277 K on the sample changer and at 300 K during acquisition of the 1H NMR 
experiments. Matching, tuning and shimming were performed automatically on each 
individual sample to reduce sample-to-sample variation. 1H NMR spectra were collected using 
a standard 1D-nuclear overhauser enhancement spectroscopy (NOESY)-presaturation and 
THE PROJECT-Carr-Purcell-Meiboom-Gill (CPMG) pulse sequences. The RF field strength for 
presaturation was 25Hz. For both experiments 8 scans were collected with a spectral width 
of 20 ppm, an acquisition time of 3.0 s and a relaxation delay of 40.0 s, which was determined 
from T1 measurements. The value of O1 was determined automatically for the first 1D-NOESY 
experiment and was used subsequently for the CPMG experiment. The total CPMG period 
was 64 ms with 180⁰ every 400 µs. For both experiments a signal-to-noise ratio of greater 
than 100:1 was achieved. A range of metabolites were identified with the aid of the software 
Chenomx NMR Suite version 8.1 (Chenomx Inc, Edmonton, Alberta) and human metabolome 
database (HMDB).  
 
Microarray analysis 
Cells at differentiation day 9 on Laminin 521/111 mix (1:3 ratio) were lysed in TRIZOL and 
stored at -80 oC. RNA extraction was performed according to the manufacturer’s instructions. 
Analysis of gene expression was performed using Affymetrix GenChip Human Genome HG-
U133 plus 2.0 array (Santa Clara, CA, USA). Microarrays were scanned with an Affymetrix 
scanner controlled by Affymetrix Microarray Suite software. 
 
Label-free LC-MS/MS proteomics analysis 
To facilitate whole proteome analysis of the three lines, quadruplicate samples of WT, DBD 
Mut and SUMO Mut cells were taken at differentiation day 9. Total protein extract was 
prepared in 1x LDS sample buffer, and 20 µg total protein for each sample was sonicated and 
boiled for 10 minutes prior to fractionation by NuPAGE 10% Bis-Tris gels using 3-(N-
morpholino) propanesulfonic acid (MOPS) buffer. Each lane of the gel was excised into 4 
slices, and peptides were prepared in parallel by in-gel tryptic digestion (Shevchenko et al., 
2007). For each sample, approximately 1µg total peptide was submitted for liquid 
chromatography coupled tandem MS (LC-MS/MS) analysis on a Q Exactive mass spectrometer 
(Thermo Scientific) coupled to an EASY-nLC 1000 liquid chromatography system (Thermo 
Scientific). Peptides were fractionated on a 75 μm x 500 mm EASY-Spray column (Thermo 
Scientific) using a 90-minute gradient. Precursor ion full scan spectra were acquired over (m/z 
300 to 1,800) with a resolution of 70,000 at m/z 200 (target value of 1,000,000 ions, maximum 
injection time 20 ms). Up to ten data dependent MS2 spectra were acquired with a resolution 
of 35,000 at m/z 200 (target value of 1,000,000 ions, maximum injection time 120 ms). Ions 
with unassigned, +1 and +8 charge state were rejected. Intensity threshold was set to 2.1 x 
104 units. Peptide match was set to preferred, dynamic exclusion duration 40 s.  
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Metabolomics data analysis 
The metabolic rate for each metabolite was quantified by normalizing the signal intensity 
against the cell number at the detected time point. The unit for the metabolic rate is then 
recorded as rate of integral area per cell. A negative rate indicates consumption, while a 
positive value means production of the metabolite. All samples were tested in triplicates.  
 
Microarray data processing and visualization 
Affymetrix gene expression data were pre-processed using ‘affyPLM’ packages of the 
Bioconductor Software (Gentleman et al., 2004). To obtain the genes with the strongest 
evidence of differential expression, a linear model fit was applied for each gene using ‘limma’ 
(Linear Models for Microarray Data) packages of the Bioconductor Software. 
 
Gene expression levels in each HNF4a-edited cell line were log2 transformed and then 
compared to the wild type control cells. Genes with a fold change greater than two over the 
wild type cell expression levels (p value <= 0.05, false discovery rate (1% FDR) corrected) were 
taken as significantly deregulated (Table S1). All samples were tested in triplicates. Processing 
and visualization (Principal Component Analysis) of data were performed using MATLAB tools 
(The MathWorks Inc., Natick, MA, USA). 
 
Gene set enrichment analysis (Gene Ontology) 
Genes which showed change of equal to or more than 2-fold were subjected to gene ontology 
(GO) analyses using the web server Enrichr (Chen et al., 2013; Kuleshov et al., 2016). The 
results of biological pathways (GOBP) were provided in Table S2. 
 
Label-free proteomics data analysis 
Data were analyzed using MaxQuant (version 1.5.8.3) (Cox and Mann, 2008; Cox et al., 2011) 
and searched against UniProtKB H. sapiens database (86749 sequences - 13/06/2012). Unless 
otherwise stated, all MaxQuant settings were default. Variable modifications of acetyl 
(Protein N-term) and oxidation (M) were considered, along with the fixed modification of 
carbamidomethyl (C). Enzyme specificity was set to trypsin/P, and a false discovery rate of 1 
% was set as a threshold at protein, peptide and site levels, and a mass deviation of 6 ppm 
was set for main search and 20 ppm for MS2 peaks. Match between runs was applied, and 
label-free quantification (LFQ) was selected. 
 
The MaxQuant proteinGroups.txt file was used for downstream proteome analysis. All decoy 
and ‘putative contaminant’ entries were removed, as were any identified only by site and 
those with fewer than 4 reported LFQ values for any single experimental group (WT, DBD Mut 
and SUMO Mut). This left 3639 protein groups comparable across all cell types. Zero LFQ 
values were replaced in Perseus (Tyanova et al., 2016), from a normal distribution of existing 
log10 LFQ intensities downshifted 1.8 and of width 0.3. Proteins were defined as statistically 
differing between groups using the Perseus unpaired two-samples Student’s t-test truncated 
by 1% permutation-based FDR using an S0 value of 0.1. No apparent specificity was entered 
as an empty cell in the spreadsheet.  
 
PCA plotting was performed using Perseus software. GOBP enrichment analysis was 
performed on Enrichr server (Table S4).  
 
Protein-protein interaction visualization was performed using a web server named STRING 
(https://string-db.org).  
 
Visualization of over-layered analysis of microarray and proteomics datasets   
A free web-based multi-omics data visualization application named PaintOmics 3 
(http://bioinfo.cipf.es/paintomics/) (Hernandez-de-Diego et al., 2018) was used to do the 
over-layered analysis of microarray and proteomics datasets.  
 
DATA AND SOFTWARE AVAILABILITY 
 
Data availability 
 
The accession number for the microarray data reported in this paper is EMBL-EBI: E-MTAB-
7951. 
 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset 
identifier PXD013737. 
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